Reliv’ International (OTCMKTS:RELV – Get Free Report) and Zymeworks (NASDAQ:ZYME – Get Free Report) are both small-cap consumer staples companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.
Risk & Volatility
Reliv’ International has a beta of -0.04, suggesting that its stock price is 104% less volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.
Valuation & Earnings
This table compares Reliv’ International and Zymeworks”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Reliv’ International | $35.06 million | 0.11 | -$440,000.00 | ($0.09) | -25.00 |
| Zymeworks | $105.96 million | 17.30 | -$81.13 million | ($1.37) | -18.33 |
Reliv’ International has higher earnings, but lower revenue than Zymeworks. Reliv’ International is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Reliv’ International and Zymeworks’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Reliv’ International | -0.61% | -1.89% | -1.31% |
| Zymeworks | -126.92% | -37.97% | -25.31% |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Reliv’ International and Zymeworks, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Reliv’ International | 0 | 0 | 0 | 0 | 0.00 |
| Zymeworks | 1 | 1 | 7 | 2 | 2.91 |
Zymeworks has a consensus price target of $38.00, suggesting a potential upside of 51.33%. Given Zymeworks’ stronger consensus rating and higher possible upside, analysts plainly believe Zymeworks is more favorable than Reliv’ International.
Insider & Institutional Ownership
7.8% of Reliv’ International shares are held by institutional investors. Comparatively, 92.9% of Zymeworks shares are held by institutional investors. 30.0% of Reliv’ International shares are held by company insiders. Comparatively, 33.5% of Zymeworks shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Zymeworks beats Reliv’ International on 10 of the 15 factors compared between the two stocks.
About Reliv’ International
Reliv' International, Inc. develops and markets nutritional supplements that address basic nutrition, specific wellness needs, weight management, and sports nutrition. The company's basic nutritional supplements are formulated to provide a balanced and complete level of supplementation for the consumer. Its principal products include Reliv Classic, Reliv Now, Innergize!, and FibRestore along with LunaRich X capsules. The company markets and sells its products through a direct selling system of independent distributors in the United States, Australia, Austria, Canada, France, Germany, Indonesia, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, and the United Kingdom. Reliv' International, Inc. was founded in 1988 and is headquartered in Chesterfield, Missouri.
About Zymeworks
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Receive News & Ratings for Reliv' International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reliv' International and related companies with MarketBeat.com's FREE daily email newsletter.
